Prolactinomas.
Antineoplastic Agents, Alkylating
/ therapeutic use
Disruptive, Impulse Control, and Conduct Disorders
/ diagnosis
Dopamine Agonists
/ therapeutic use
Female
Galactorrhea
/ etiology
Humans
Hyperprolactinemia
/ etiology
Hypogonadism
/ etiology
Pituitary Neoplasms
/ complications
Pregnancy
Prolactin
/ blood
Prolactinoma
/ complications
Sella Turcica
/ diagnostic imaging
Temozolomide
/ therapeutic use
Cabergoline
Dopaminergic agonists
Hyperprolactinemia
Impulse control disorder
Prolactinomas
Journal
Presse medicale (Paris, France : 1983)
ISSN: 2213-0276
Titre abrégé: Presse Med
Pays: France
ID NLM: 8302490
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
31
12
2020
revised:
31
08
2021
accepted:
12
10
2021
pubmed:
24
10
2021
medline:
16
12
2021
entrez:
23
10
2021
Statut:
ppublish
Résumé
Hyperprolactinemia, defined by a level of serum prolactin above the standard upper limit of normal range, is a common finding in clinical practice and prolactinomas are the main pathological cause. Prolactinomas lead to signs and symptoms of hormone oversecretion, such as galactorrhea and hypogonadism, as well as symptoms of mass effect, including visual impairment, headaches and intracranial hypertension. Diagnosis involves prolactin measurement and sellar imaging, but several pitfalls are involved in this evaluation, which may difficult the proper management. Treatment is medical in the majority of cases, consisting of dopamine agonists, which present high response rates, with a very favorable safety profile. Major adverse effects that should be monitored consist of cardiac valvulopathy and impulse control disorders. Other treatment options include surgery and radiotherapy. Temozolomide may be used for aggressive or malignant carcinomas. Finally, pregnancy outcomes are similar to general population even when dopamine agonist treatment is maintained.
Identifiants
pubmed: 34687915
pii: S0755-4982(21)00019-1
doi: 10.1016/j.lpm.2021.104080
pii:
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Dopamine Agonists
0
Prolactin
9002-62-4
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104080Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.